Monday, April 13, 2026<\/p>\n
Smaller gene-editing system could expand treatment options for cancer, ALS and other diseases. <\/p>\n
A\u00a0National Institutes of Health (NIH)-funded research team\u00a0has\u00a0discovered an\u00a0enhanced\u00a0CRISPR<\/a>\u00a0gene-editing system that could enable targeted delivery inside the human body \u2014 a key step toward broader clinical use.\u00a0Researchers\u00a0identified\u00a0a naturally occurring enzyme, Al3Cas12f, that is small enough to fit into adeno-associated virus vectors,\u00a0a leading\u00a0targeted\u00a0delivery method for gene therapies. They then engineered an enhanced version that dramatically improved gene-editing performance in human cells.\u00a0<\/p>\n The advance addresses a major limitation in CRISPR technology. Commonly used gene-editing proteins are too large for targeted delivery systems, restricting clinical applications to cells\u00a0modified\u00a0outside the body, such as blood and bone marrow.\u00a0<\/p>\n \u201cSmart delivery of gene editing\u00a0systems\u00a0is a powerful notion\u00a0with broad clinical implications, and this\u00a0basic science finding takes us\u00a0a significant step\u00a0toward that future,\u201d\u00a0said\u00a0Erica Brown, Ph.D.,\u00a0acting\u00a0director of NIH\u2019s National Institute of General Medical Sciences (NIGMS).\u00a0<\/p>\n Using imaging and machine learning tools, researchers at the University of Texas at Austin analyzed the enzyme\u2019s structure. They found it forms a more stable and tightly connected complex than\u00a0other\u00a0enzymes\u00a0of\u00a0a similar size, allowing it to function more effectively in human cells.\u00a0\u00a0<\/p>\n \u201cThe\u00a0expanded\u00a0interface means the enzyme is\u00a0much more stable.\u00a0Compared to the others\u00a0we looked at,\u00a0Al3Cas12f\u00a0basically\u00a0comes\u00a0preassembled and ready to go shortly\u00a0after its pieces are produced,\u201d\u00a0said corresponding author David Taylor, Ph.D., a\u00a0molecular bioscience\u00a0professor\u00a0at UT Austin.\u00a0<\/p>\n The team then engineered a variant, known as Al3Cas12f RKK, which significantly improved editing efficiency from less than 10% to more than 80% across tested targets. In a commonly edited region of the genome, efficiency reached 90%.\u00a0<\/p>\n Of the\u00a0many variants\u00a0the team\u00a0produced, Al3Cas12f RKK\u00a0stood above the rest. The team\u00a0introduced instructions for\u00a0RKK\u00a0directly\u00a0into\u00a0a line of human cells originally\u00a0isolated\u00a0from a patient with leukemia.\u00a0Mutations in several of the genes they aimed to edit were associated with diseases such as cancer, atherosclerosis, and amyotrophic lateral sclerosis (ALS).\u00a0<\/p>\n The authors expect to build on their encouraging results.\u00a0They next\u00a0plan to\u00a0conduct tests of the nuclease\u2019s performance when packaged into\u00a0AAV\u00a0vectors, which, if\u00a0successful, could\u00a0bring gene editing therapy for\u00a0many diseases\u00a0much closer to reality.\u00a0<\/p>\n This research was supported in part by NIGMS through grant\u00a0R35GM138348.\u00a0<\/p>\n NIGMS is a part of the National Institutes of Health that supports basic research to increase our understanding of biological processes and lay the foundation for advances in disease diagnosis, treatment, and prevention. For more information on the Institute’s research and training programs, visit\u202fhttps:\/\/www.nigms.nih.gov<\/a>.\u202f\u00a0<\/p>\n About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov<\/a>.<\/p>\n NIH\u2026Turning Discovery Into Health\u00ae<\/p>\n Reference<\/p>\n